Theragenics lays off workers, restructures development programs

Theragenics plans to lay off 23 workers as it concentrates on its core cancer products and its newly acquired CP Medical, which makes medical devices. Theragenics will discontinue programs for macular degeneration, breast cancer and more. The company says it is looking to its business operations that have the best potential for generating revenue.

- read this AP story for more

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.